论文部分内容阅读
目的评价重组人血小板生成素(rhTPO)治疗白血病化疗后血小板(PLT)减少症的疗效和安全性。方法 96例白血病患者随机分为治疗组(重组人血小板生成素,rhTPO)与对照组(重组人白介素-11,rhIL-11),分别皮下注射,观察外周血小板的变化。结果治疗组血小板的最低值和恢复的最高值显著高于对照组;治疗组的PLT<50×109L-1的持续时间、恢复到70×109L-1和125×109L-1所需要的时间,显著低于对照组所需时间;治疗组不良反应少且较轻微。结论重组人血小板生成素(rhTPO)治疗急性白血病化疗后的血小板减少症疗效显著且安全性好。
Objective To evaluate the efficacy and safety of recombinant human thrombopoietin (rhTPO) in the treatment of thrombocytopenia (PLT) after leukemia chemotherapy. Methods 96 patients with leukemia were randomly divided into treatment group (recombinant human thrombopoietin, rhTPO) and control group (recombinant human interleukin-11, rhIL-11), were injected subcutaneously to observe the changes of peripheral platelets. Results The lowest value of platelet and the highest value of recovery in treatment group were significantly higher than those in control group. The duration of PLT <50 × 109 L-1, the time required to recover to 70 × 109 L-1 and 125 × 109 L-1 in treatment group were Significantly lower than the control group of time; adverse reactions in the treatment group less and less. Conclusion Recombinant thrombopoietin (rhTPO) is effective and safe in the treatment of thrombocytopenia after chemotherapy for acute leukemia.